1CM
ARIA

1492 Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

1492 Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-202,500
Closed -$1.5M – 120
2016
Q2 		$1.5M Hold
202,500
– – 1.34% 28
2016
Q1 		$1.29M Hold
202,500
– – 1.09% 34
2015
Q4 		$1.27M Hold
202,500
– – 0.92% 32
2015
Q3 		$1.18M Buy
202,500
+140,000
+224% +$1.08M 0.84% 33
2015
Q2 		$517K Buy
+62,500
New +$553K 0.33% 76

Other funds holding ARIA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

1492 Capital Management's ARIA Position: Q3 2016 in Review

1492 Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2016, closing a stake of 202,500 shares — an estimated $1.5M sold.

1492 Capital Management first reported a position in ARIA in Q2 2015 and held it in 5 quarters. The position peaked at $1.5M in Q2 2016. 202 funds tracked by Wall St. Rank hold ARIA as of Q3 2016.

  • 1492 Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • 1492 Capital Management sold 202,500 Ariad Pharmaceuticals Inc shares in Q3 2016, an estimated $1.5M.
  • 1492 Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2015 and held it in 5 quarters.
  • 1492 Capital Management's Ariad Pharmaceuticals Inc position peaked at $1.5M in Q2 2016.
  • 202 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2016.

Based on 1492 Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.